

# **Product List** FY' 22-23

retroapi.com







## About

Metrochem is a customer-driven company with a focus on chemistry and innovation. At Metrochem, we understand our responsibility to deliver high quality pharmaceutical products which keeps us pushing ourselves to continuously improve and achieve our vision of providing reliable end to end pharmaceutical support in high growth and high impact therapeutic areas.

We began our humble journey in the year 2004, with a single unit Active Pharmaceutical Ingredient (API) manufacturing facility with 2 products in our pipeline. Quickly, we backward integrated to intermediates by starting our Intermediate manufacturing facility in 2005. Over the course of years, we started 2 more intermediate manufacturing facilities to fulfill our upstream needs.

Since our inception, we focused on generating value through vertical integration and continuous improvement of our infrastructure and manpower. This foresight about the importance of being vertically integrated allowed us to be always one step ahead of the competition. It helped us to better control the quality of ingredients that go into the final product, and have better command on the pricing along with an extreme efficiency in terms of deliveries. We have also focused on hiring the right, qualified teams to ensure the critical safety, and oversee the Production, QA, QC and Regulatory activities. Over the years, our ground-level efforts, coupled with our expertise in product development helped Metrochem clear several regulatory audits such as USFDA, PMDA, WHO-GMP and enabled us to become a strong, reliable and trustworthy partner to our clients globally.

At Metrochem, we never rest, we are always up for bigger and better challenges. To extend our impeccable service to the global markets and to meet the increasing demand across our portfolio, we have initiated the construction of a green-field 10 acre Vizag facility in 2012. It was built as a gateway to Metrochem's foray into the regulatory markets.

Our plants have an overall reactor volume of 3000KL with a range of 0.5KL to 15KL. The units are manned by over 3000 well-qualified and experienced Pharma professionals. In the financial year 2022-23 alone we have filed 19 USDMFs and are ranked #1 in the world, with this our total USDMF filings stand at 53.



## **Research & Development Focus**

At Metrochem, we have a strong zeal for innovation and readiness for investments in Research and Development. This attitude has trickled down from the top, with our founder Dr. N.V.Rao being an expert in organic chemistry. We have extensively worked on and delivered new products across a wide variety of therapeutic segments and as a company we have built strong expertise in new product development.

With R&D efficiency as a core competency, Metrochem expanded its product portfolio from 2 to 300+ within a very short span and this number has been continuously increasing. To date, Metrochem has filed more than 102 patents and 17 patents have been successfully granted.

We have 3 stand-alone R&D centers located in Hyderabad with State-of-the-art analytical facilities and over 300 scientists. Our R&D focused culture allows us and our teams to work with passion and commitment, and therefore research out novel and economical routes efficiently.

We have invested \$5 million in 2019 alone to further upgrade our Analytical R&D. Annually, we invest >5% of our revenue in Research & Development activities. We also have a dedicated Formulation R&D center and a Process R&D lab that focuses on the application of flow chemistry and chemical engineering principles to improve our manufacturing capabilities, and achieve an overall operational excellence.

## **GENERIC API PORTFOLIO**

PRODUCT NAME		FILING	S	THERAPEUTIC CATEGORY /
I KODOCI NAME	DMF	USDMF	CEP	INDICATION
Antazoline (Hydrochloride & Phosphate)	<ul> <li>Image: A second s</li></ul>	<b>×</b>	✓	Antihistamine
Bepotastine Besilate	<b>~</b>	0	R	Antihistamine
Bilastine	<b>~</b>		ß	Antihistamine
Cinitapride Hydrogen Tartrate	<b>~</b>	0	S	Antiemetic
Clopidogrel Bisulphate (Form I & II)	<ul> <li>Image: A start of the start of</li></ul>		$\checkmark$	Antiplatelet
Dabigatran Etexilate Mesylate	<b>~</b>	<ul> <li>Image: A second s</li></ul>	ß	Anticoagulant / Antithrombotic
Dexketoprofen Trometamol	<b>~</b>	<b>~</b>	ß	Analgesic
Dexlansoprazole (Sesquihydrate & Amorphous)	<b>~</b>		R	Antiulcerative
Dexrabeprazole Sodium	<b>~</b>	S	R	Antiulcerative
Dimetindene Maleate	<b>~</b>	ß	$\checkmark$	Antihistamine
Elobixibat Hydrate	<b>~</b>	<b>×</b>	ß	Irritable Bowel Syndrome - Constipation
Esomeprazole (Sodium, Magnesium Dihydrate and Trihydrate)	<b>~</b>	<b>~</b>	$\checkmark$	Antiulcerative
Etoricoxib	<b>~</b>		R	Analgesic
Febuxostat (All Forms)	<b>~</b>		ß	Antirheumatic
Flecainide Acetate	S	S	S	Antiarrhythmic
Fosravuconazole	<b>~</b>	ß	R	Antifungal
Gabapentin	<b>~</b>	ß	R	Antiepileptic
Ilaprazole	<b>~</b>	0	0	Antiulcerative
Imeglimin Hydrochloride	<ul> <li>Image: A start of the start of</li></ul>	✓	R	Antidiabetic

Available () Initiated S Scheduled B Ready to file

### **GENERIC API PORTFOLIO**

PRODUCT NAME		FILING		THERAPEUTIC CATEGORY /
	DMF	USDMF	CEP	INDICATION
traconazole		0	0	Antifungal
Lacosamide		ß	R	Antiepileptic
Lansoprazole			<b>√</b>	Antiulcerative
Levocarnitine	S	S	S	Carnitine Deficiency in patients with Kidney Dise
Levocetirizine Dihydrochloride	✓		ß	Antihistamine
Loxoprofen Sodium	✓		0	Analgesic
Montelukast Sodium	<ul> <li>Image: A start of the start of</li></ul>	0	0	Antiasthmatic
Nicardipine	<ul> <li>Image: A start of the start of</li></ul>	R	R	Antihypertensive
Omeprazole (Magnesium & Sodium)	<ul> <li>Image: A start of the start of</li></ul>	<b>~</b>	<ul> <li>✓</li> </ul>	Antiulcerative
Oxiconazole Nitrate	✓		ß	Antifungal
P <b>antoprazole</b> (Magnesium, Sodium, Sesquihydrate)	<ul> <li>Image: A start of the start of</li></ul>	<b>~</b>	$\checkmark$	Antiulcerative
Posaconazole	<ul> <li>Image: A start of the start of</li></ul>	<b>~</b>	R	Antifungal
Rabeprazole (Sodium)	<ul> <li>Image: A start of the start of</li></ul>		$\checkmark$	Antiulcerative
Ranolazine	<ul> <li>Image: A start of the start of</li></ul>		ß	Antianginal
Silodosin (α & β forms)	<ul> <li>Image: A start of the start of</li></ul>		S	Benign Prostatic Hyperplasia
Feneligliptin Hydrobromide Hydrate	<ul> <li>Image: A start of the start of</li></ul>	<b>~</b>	R	Antidiabetic
Vigabatrin	R	ß	S	Antiepileptic
Vildagliptin	✓	ß	ß	Antidiabetic

## DVANCED API PORTFOL

The following products are intended to be suppplied solely for uses reasonably relating to the testing and development of information, for regulatory submission, strictly according to the section 107A of the Indian Patents Act, 1970.

		FILING	5	THERAPEUTIC CATEGORY /	
PRODUCT NAME	DMF	USDMF	СЕР	INDICATION	
Alogliptin Benzoate	$\checkmark$	✓	R	Antidiabetic	
Apixaban	V	<ul> <li>Image: A start of the start of</li></ul>	R	Anticoagulant / Antithrombotic	
Azilsartan Medoxomil Potassium	$\checkmark$	R	R	Antihypertensive	
Bempedoic acid	$\checkmark$	<ul> <li>Image: A start of the start of</li></ul>	R	Antihyperlipidemic	
Cenobamate	R	R	ß	Antiepileptic	
Dapagliflozin (Propanediol Monohydrate, Amorphous, Citrate)	$\checkmark$		R	Antidiabetic	
Edoxaban Tosylate Monohydrate	$\checkmark$		R	Anticoagulant / Antithrombotic	
Empagliflozin	$\checkmark$	<ul> <li>Image: A start of the start of</li></ul>	R	Antidiabetic	
Isavuconazonium Sulfate	$\checkmark$		S	Antifungal	
Lasmiditan	R	R	R	Antimigraine	
Lurasidone Hydrochloride	$\checkmark$	✓	R	Antipsychotic	
Migalastat Hydrochloride	$\checkmark$	<ul> <li>Image: A start of the start of</li></ul>	ß	Fabry Disease	
Mirabegron	$\checkmark$		S	Over Active Bladder	
Ozenoxacin	$\checkmark$	✓	R	Antibiotic	
Prucalopride Succinate	$\checkmark$	✓	R	Chronic Idiopathic Constipation	
Saxagliptin Hydrochloride	$\checkmark$	0	0	Antidiabetic	
Tedizolid Phosphate	$\checkmark$	✓	ß	Antibiotic	
Tofacitinib Citrate	$\checkmark$	✓	ß	Antirheumatic	
Vonoprazan Fumarate	$\checkmark$	Image: A start of the start	ß	Antiulcerative	

🗹 Available 🕕 Initiated 🛛 Scheduled 🚯 Ready to file

## **DEVELOPMENT API PORTFOLIO**

The following products are intended to be suppplied solely for uses reasonably relating to the testing and development of information, for regulatory submission, strictly according to the section 107A of the Indian Patents Act,1970.

	STATUS			THERAPEUTIC CATEGORY /
PRODUCT NAME	LAB VALIDATION	SCALE UP	PROCESS VALIDATION	INDICATION
Acotiamide Hydrochloride			$\checkmark$	Gastroprokinetic
Elagolix Sodium			<ul> <li>✓</li> </ul>	Pain associated with Endometriosis
Eltrombopag			<ul> <li>Image: A second s</li></ul>	Thrombocytopenia
Fenticonazole Nitrate			<ul> <li>Image: A set of the set of the</li></ul>	Antifungal
Lercanidipine Hydrochloride			<ul> <li>✓</li> </ul>	Antihypertensive
L-Glutamine			$\checkmark$	Antianaemic
Lifitegrast			<ul> <li>✓</li> </ul>	Dry Eye Disease
Siponimod			✓	Multiple Sclerosis
Stiripentol			$\checkmark$	Antiepileptic
Tegoprazan			$\checkmark$	Antiulcerative
Topiroxostat			$\checkmark$	Antigout
Upadacitinib Tartrate			✓	Antirheumatic
Vortioxetine Hydrobromide			✓	Antidepressant
Brexpiprazole		✓		Antipsychotic
Brivaracetam		$\checkmark$		Antiepileptic
Crisaborole		$\checkmark$		Atopic Dermatitis
Efinaconazole		$\checkmark$		Antifungal
Epalrestat		$\checkmark$		Diabetic Neuropathy
Ertugliflozin L-PGA		$\checkmark$		Antidiabetic
Ferric Maltol		$\checkmark$		Antianaemic
Fingolimod Hydrochloride		$\checkmark$		Multiple Sclerosis
Ipragliflozin		$\checkmark$		Antidiabetic
Ivabradine Hydrochloride		$\checkmark$		Heart Failure
Mavacamten		<ul> <li>✓</li> </ul>		Hypertrophic Cardiomyopathy

## **DEVELOPMENT API PORTFOLIO**

The following products are intended to be suppplied solely for uses reasonably relating to the testing and development of information, for regulatory submission, strictly according to the section 107A of the Indian Patents Act,1970.

	STATUS			THERAPEUTIC CATEGORY /
PRODUCT NAME	LAB VALIDATION	SCALE UP	PROCESS VALIDATION	
Ponesimod		$\checkmark$		Multiple Sclerosis
Relugolix		$\checkmark$		Uterine Fibroids
Rimegepant		$\checkmark$		Antimigraine
Selexipag		$\checkmark$		Pulmonary Arterial Hypertension
Tapinarof (or) Benvitimod		$\checkmark$		Plaque Psoriasis
Trelagliptin Succinate		✓		Antidiabetic
Apremilast	<ul> <li>Image: A start of the start of</li></ul>			Antipsoriatic
Baloxavir Marboxil	<ul> <li>Image: A start of the start of</li></ul>			Antiviral
Canagliflozin Hemihydrate				Antidiabetic
Chiglitazar/Carfloglitazar				Antidiabetic
Daprodustat				Anaemia in Chronic Kidney Disease
Dolutegravir	Image: A start of the start			Antiretroviral
Edaravone	<ul> <li>Image: A start of the start of</li></ul>			Amyotrophic Lateral Sclerosis (ALS)
Ezetimibe				Antihyperlipidemic
Faropenem				Antibiotic
Ferric Carboxymaltose				Antianaemic
Ferric Derisomaltose/Iron Isomaltoside	<ul> <li>Image: A start of the start of</li></ul>			Antianaemic
Ferumoxytol				Antianaemic
Fexuprazan	<ul> <li>Image: A start of the start of</li></ul>			Antiulcerative
Finerenone				Diabetic Nephropathy
Fosfomycin Trometamol	<ul> <li>Image: A start of the start of</li></ul>			Antibiotic
Garenoxacin Mesylate				Antibiotic
Ivacaftor				Cystic Fibrosis
Levomilnacipran Hydrochloride				Antidepressant
Linagliptin	✓			Antidiabetic

## **DEVELOPMENT API PORTFOLIO**

The following products are intended to be suppplied solely for uses reasonably relating to the testing and development of information, for regulatory submission, strictly according to the section 107A of the Indian Patents Act,1970.

	STATUS			THERAPEUTIC CATEGORY /
PRODUCT NAME	LAB VALIDATION	SCALE UP	PROCESS VALIDATION	INDICATION
Lisinopril				Antihypertensive
Molnupiravir (Cytidine)	✓			Antiviral
Niclosamide	✓			Anthelmintic
Nintedanib	×			Idiopathic Pulmonary Fibrosis
Nirmatrelvir	Image: A state of the state			Antiviral
Obeticholic Acid				Primary Biliary Cholangitis
Opicapone	✓			Parkinson's Disease
Pemafibrate	✓			Antihyperlipidemic
Perampanel				Antiepileptic
Pirfenidone				Idiopathic Pulmonary Fibrosis
Rifaximin				Irritable Bowel Syndrome
Riociguat				Pulmonary Arterial Hypertension
Rivaroxaban	×			Anticoagulant / Antithrombotic
Roxadustat	×			Anaemia in Chronic Kidney Disease
Safinamide				Parkinson's Disease
Sodium Zirconium Cyclosilicate				Hyperkalemia
Suvorexant				Insomnia
Tafenoquine Succinate				Antimalarial
Tecarfarin				Anticoagulant / Antithrombotic
Tenatoprazole Sodium				Antiulcerative
Tolvaptan				Autosomal Dominant Polycystic
Vadadustat				Anaemia in Chronic Kidney Disease
Vericiguat				Heart Failure
Vibegron				Over Active Bladder
Zavegepant	✓			Antimigraine

#### **PROSPECTIVE WISHLIST**

PRODUCT NAME	THERAPEUTIC CATEGORY / INDICATION
Abrocitinib	Atopic Dermatitis
Atogepant	Antimigraine
Bexagliflozin	Antidiabetic
Candesartan	Antihypertensive
Cariprazine	Antidepressant
Ciclopirox	Seborrhoeic Dermatitis
Dimethyl Fumarate	Multiple Sclerosis
Eliglustat	Gaucher's Disease
Eslicarbazepine	Antiepileptic
Etifoxine	Antipsychotic
Flurbiprofen	Antibiotic
Galantamine	Alzheimer's Disease
Gliclazide	Antidiabetic
Letermovir	Antiviral
Linezolid	Antibiotic
Linzagolix	Uterine Fibroids
Lumateperone	Antipsychotic
Macitentan	Pulmonary Arterial Hypertension
Mirogabalin	Neuropathic Pains
Netupitant	Antiemetic

#### **PROSPECTIVE WISHLIST**

PRODUCT NAME	THERAPEUTIC CATEGORY / INDICATION
Opelconazole	Antifungal
Osilodostat	Cushing's Syndrome
Oteseconazole	Antifungal
Ozanimod	Multiple Sclerosis
Plazomicin	Antibiotic
Prulifloxacin	Antibiotic
Remogliflozin	Antidiabetic
Risdiplam	Spinal Muscular Atrophy
Rosuvastatin	Antihyperlipidemic
Ruxolitinib	Atopic Dermatitis, Myelofibrosis
Sacubitril	Heart Failure
Sarecycline	Acne Vulgaris
Sitagliptin	Antidiabetic
Sparsentan	IgA Nephropathy
Sulconazole Nitrate	Antifungal
Teriflunomide	Multiple Sclerosis
Ubrogepant	Antimigraine
Vilanterol	Chronic Obstructive Pulmonary Disease
Vilazodone	Antidepressant
Viloxazine	Attention Deficit Hyperactivity Disorder
Zonisamide	Antiepileptic

#### **USDMF FILINGS**

PRODUCT NAME	USDMF NUMBER	PRODUCT NAME	USDMF NUMBER
Oxiconazole Nitrate	34173	Tofacitinib Citrate	35976
Antazoline Phosphate USP	34330	Dapagliflozin Propanediol Monohydrate	36048
Clopidogrel Bisulfate USP	34334	Bempedoic Acid	36085
Etoricoxib	34537	Imeglimin Hydrochloride	36107
Silodosin	34538	Silodosin (βForm)	36132
Dexketoprofen Trometamol	34732	Loxoprofen Sodium Hydrate	36114
Levocetirizine Dihydrochloride USP	34731	Dapagliflozin (Amorphous)	36608
Omeprazole USP	34759	Zinc Chloride USP	36964
Lurasidone Hydrochloride	34756	Zinc Sulfate Heptahydrate USP	36963
Prucalopride Succinate	34790	Mirabegron	36973
Vonoprazan Fumarate	35150	Bilastine	36965
Dexlansoprazole	34971	Isavuconazonium Sulfate	36974
Empagliflozin	35345	Cupric Chloride Dihydrate USP	36961
Omeprazole Magnesium USP	35390	Selenious Acid USP	36958
Rabeprazole Sodium USP	35344		
Esomeprazole Magnesium Trihydrate USP	35400	Manganese Sulfate Monohydrate USP	36960
Lansoprazole USP	35485	Cupric Sulfate Pentahydrate USP	36962
Ozenoxacin	35487	Chromic Chloride Hexahydrate USP	36959
Esomeprazole Magnesium Dihydrate USP	35519	Posaconazole (Form - I)	36969
Apixaban	35518	Ranolazine	37339
Posaconazole	35517	Elobixibat	37340
Febuxostat USP	35578	Dabigatran Etexilate Mesylate	37633
Tedizolid Phosphate	35515	Rabeprazole Sodium (Form - Y)	37630
Pantoprazole Magnesium	35516	Fosravuconazole L-Lysine Ethanolate	37342
Febuxostat (Form-A) USP	35797	Edoxaban Tosylate Monohydrate	37896
Teneligliptin Hydrobromide Hydrate	35576	Alogliptin Benzoate	37908
Pantoprazole Sodium USP	35577	Migalastat Hydrochloride	37632

#### **CEP FILINGS**

PRODUCT NAME	CEP NUMBER
Antazoline Hydrochloride EP	CEP 2020-060
Clopidogrel Hydrogen Sulfate EP	CEP 2020-093
Copper Sulfate Pentahydrate	CEP 2022-438
Dimetindene Maleate	CEP 2021-080
Esomeprazole Magnesium Dihydrate EP	CEP 2021-022
Esomeprazole Magnesium Trihydrate EP	CEP 2020-386
Esomeprazole Sodium EP	CEP 2020-214
Lansoprazole	CEP 2021-009
Manganese Sulfate Monohydrate Ph. Eur.	CEP 2022-464
Omeprazole EP	CEP 2020-182
Omeprazole Magnesium EP	CEP 2020-380
Omeprazole Sodium EP	CEP 2020-372
Pantoprazole Sodium Sesquihydrate	CEP2021-168
Rabeprazole Sodium Hydrate (RBL process)	CEP 2022-429
Rabeprazole Sodium Hydrate (Y Form)	CEP 2022-468
Rabeprazole Sodium Hydrate EP	CEP 2020-387
Zinc Chloride	CEP 2022-426
Zinc Sulfate Heptahydrate	CEP 2022-422

#### **NMPA FILINGS**

PRODUCT NAME	MONOGRAPH
Rabeprazole Sodium	IHS
Lansoprazole	Ph. Eur
Omeprazole (EA Route)	Ph. Eur
Omeprazole Sodium	Ph. Eur
Esomeprazole Magnesium Trihydrate	Ph. Eur
Lurasidone Hydrochloride	JP
Silodosin	IHS
Pantoprazole Sodium Sesquihydrate	USP

#### **JDMF FILINGS**

PRODUCT NAME	JDMF NUMBER
Rabeprazole Sodium	221MF10282
Lansoprazole	223MF10044
Levocetirizine Dihydrochloride	302MF10110
Clopidogrel Hydrogen Sulfate	304MF10071

#### **MFDS FILINGS**

PRODUCT NAME	FACILITY	STATUS
Esomeprazole Magnesium Dihydrate	I	✓
Esomeprazole Magnesium Trihydrate	I & IV	✓
Esomeprazole Sodium	Ι	✓
Rabeprazole Sodium	Ι	✓
Montelukast Sodium	I	8
Clopidogrel Bisulfate (Form - I)	IV	S
Febuxostat (Form - B)	IV	S
Dexlansoprazole	IV	S
Vonoprazan Fumarate	IV	S
Levocetirizine Dihydrochloride	IV	S
S-Pantoprazole Sodium	Ι	S
Rabeprazole Chloro Compound	С	S

Approved S Submitted

#### **CADIFA FILINGS**

PRODUCT NAME	REFERENCE NUMBER	
Clopidogrel Bisulfate (CPB)	25351498617202218	
Esomeprazole Sodium (ESS)	25351172172202249	
Empagliflozin (PRL)	25351003836202310	



## **Metrochem API** Private Limited

#### **Corporate Office:**

Metrochem API Private Limited #The Watermark, 3rd Floor, Plot No 11, Survey No 9, Whitefields, Kondapur, Hitech City, Hyderabad-500084, Telangana State, India. Tel: +91-040-69069999

i webleads@metroapi.com

#### Vizag Manufacturing Unit:

Metrochem API Private Limited #Plot No. 40B, 60B, JN Pharma City, Parwada, Vishakapatnam-531021, Andhra Pradesh, India. DUNS No: 72-523-8161 FEI: 3014289163

reference www.metroapi.com